The Reagan-Udall Foundation for the Food and Drug Administration is collaborating with Friends of Cancer Research (Friends) to launch the COVID-19 Evidence Accelerator. The Accelerator is bringing together the country’s leading experts in health data aggregation and analytics in a unified effort to share insights, compare results, and answer key questions about COVID-19 treatment and response as quickly as possible. COTA is actively participating in this collaboration, presenting key findings from ongoing research with Hackensack-Meridian Health (HMH) involving observational, real-world studies of more than 3,000 hospitalized COVID-19 patients.

Traditionally, COTA’s expertise in real-world evidence (RWE) has been applied to cancer research. However, in response to the COVID-19 pandemic, the company has redirected a significant amount of its resources, analyzing data from affected patients at HMH to reveal valuable insights that can be shared with front line care providers who are learning how to treat this virus in real time without precedent.

Time is our greatest enemy in the fight against COVID-19 and RWE will play an instrumental role in improving our understanding of this virus. By analyzing the data of these patients days or even hours after it is collected, COTA is highlighting commonalities and variations in care and their associated outcomes, as well as risk factors to inform decision making at the point of care. You can read more about the ongoing work of the COVID-19 Evidence Accelerator here.